Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JITENDRA I VASANDANI

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1194707406
CMS profile
235624
Location
LUBBOCK, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$30,873.84

453 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $19,587.00 6
Food and Beverage $6,977.60 423
Travel and Lodging $4,277.29 19
Education $31.95 5

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 10; records 101–150 of 453 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JITENDRA I VASANDANI

NPI 1194707406 · CMS profile ID 235624

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

LUBBOCK, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 10; records 101–150 of 453 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194707406?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JITENDRA I VASANDANI, NPI 1194707406, CMS profile ID 235624. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 10; records 101–150 of 453 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194707406?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JITENDRA I VASANDANI, NPI 1194707406, CMS profile ID 235624. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 10; records 101–150 of 453 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194707406?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JITENDRA I VASANDANI, NPI 1194707406, CMS profile ID 235624, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 10; records 101–150 of 453 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1194707406?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

453 matching records · $30,873.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 453 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 453.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $5.1409/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672922359 CMS
SANOFI-AVENTIS U.S. LLC $9.7709/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694143579 CMS
UCB, Inc. $21.3209/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688353153 CMS
GENZYME CORPORATION $18.0509/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694207505 CMS
E.R. Squibb & Sons, L.L.C. $10.4909/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651265099 CMS
Horizon Therapeutics plc $15.7109/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691519035 CMS
Janssen Biotech, Inc. $5.1909/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658766181 CMS
Novartis Pharmaceuticals Corporation $7.5309/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660052655 CMS
Novartis Pharmaceuticals Corporation $19.5809/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660052659 CMS
E.R. Squibb & Sons, L.L.C. $11.8809/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651265107 CMS
AbbVie, Inc. $18.7309/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647795055 CMS
Amgen Inc. $8.2909/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662511799 CMS
Celgene Corporation $5.7808/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672874261 CMS
Amgen Inc. $13.6908/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662511797 CMS
PFIZER INC. $10.5308/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672898067 CMS
UCB, Inc. $18.5608/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688301857 CMS
Radius Health, Inc. $17.0508/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683952857 CMS
Genentech USA, Inc. $6.5808/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681365039 CMS
GlaxoSmithKline, LLC. $10.0808/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670394205 CMS
GlaxoSmithKline, LLC. $2.2408/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671219159 CMS
Lilly USA, LLC $5.4308/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657900321 CMS
Genentech USA, Inc. $7.9308/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681398285 CMS
Janssen Biotech, Inc. $19.2508/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658766177 CMS
UCB, Inc. $12.0008/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688320131 CMS
UCB, Inc. $1.2908/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688320133 CMS
Horizon Therapeutics plc $18.0308/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691519033 CMS
PFIZER INC. $4.9908/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672747559 CMS
PFIZER INC. $6.7408/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672751773 CMS
Novartis Pharmaceuticals Corporation $18.6908/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660052657 CMS
AbbVie, Inc. $23.4008/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647795073 CMS
Amgen Inc. $4.8608/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662511659 CMS
Lilly USA, LLC $1.0008/19/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657903801 CMS
Amgen Inc. $74.2408/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662511697 CMS
Amgen Inc. $74.2508/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662511705 CMS
Novartis Pharmaceuticals Corporation $19.9008/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660052653 CMS
PFIZER INC. $7.0208/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672735425 CMS
Amgen Inc. $17.4508/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662511653 CMS
AbbVie, Inc. $4.0108/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647795035 CMS
E.R. Squibb & Sons, L.L.C. $8.9308/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651265095 CMS
Flexion Therapeutics, Inc. $1.0908/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705848663 CMS
Flexion Therapeutics, Inc. $18.8408/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705848665 CMS
Horizon Therapeutics plc $14.3408/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691519029 CMS
Janssen Biotech, Inc. $7.4408/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658766173 CMS
Takeda Pharmaceuticals U.S.A., Inc. $7.5908/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681684657 CMS
Amgen Inc. $21.0308/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662511791 CMS
Genentech USA, Inc. $8.8108/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681390265 CMS
Horizon Therapeutics plc $15.9008/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691519025 CMS
PFIZER INC. $10.3208/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672748937 CMS
AbbVie, Inc. $19.2008/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647795053 CMS
Novartis Pharmaceuticals Corporation $11.6708/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660052637 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $30,873.84 453
PY2020 $6,482.45 321
PY2021 $5,547.84 335
PY2022 $14,470.55 322
PY2023 $11,434.84 322
PY2024 $6,625.08 268
PY2025 $5,923.89 247

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,033.46 1
PY2025 Principal investigator $1,027,272.44 92
PY2024 Recipient $75,058.86 4
PY2024 Principal investigator $921,309.67 212
PY2023 Principal investigator $970,660.05 214
PY2022 Principal investigator $1,192,984.51 393
PY2021 Principal investigator $840,813.73 180
PY2020 Principal investigator $833,456.07 121
PY2019 Principal investigator $504,779.65 51

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

93 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Sun Pharmaceutical Industries Inc. $951.34 12/17/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
INSPIRE LTE study No dispute reported 06/30/2026 1246432842
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,093.84 12/17/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH D
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289760
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,601.96 12/17/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH D
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289762
Principal investigator 1 ABBVIE INC. $2,374.60 12/04/2025 Non-covered Recipient Entity
JITENDRA VASANDANI-MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202527130
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,566.88 12/01/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH D
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288861
Principal investigator 1 Sun Pharmaceutical Industries Inc. $17,251.78 11/19/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
INSPIRE LTE study No dispute reported 06/30/2026 1246432855
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,665.44 11/19/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH D
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288481
Principal investigator 1 Sun Pharmaceutical Industries Inc. $9,773.40 11/10/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246432911
Principal investigator 1 Sun Pharmaceutical Industries Inc. $7,779.02 11/07/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432907
Principal investigator 1 ABBVIE INC. $3,247.90 11/04/2025 Non-covered Recipient Entity
JITENDRA VASANDANI-MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202520161
Principal investigator 1 Sun Pharmaceutical Industries Inc. $951.34 10/22/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
INSPIRE LTE study No dispute reported 06/30/2026 1246432851
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $24,747.92 10/15/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH D
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286939
Principal investigator 1 SANOFI US SERVICES INC. $9,577.20 10/14/2025 Non-covered Recipient Entity
Jitendra Vasandani Md Pa Jitendra Vasandani Md Pa Dba West Texas Clinical Research
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226082805
Principal investigator 1 ABBVIE INC. $4,341.00 10/09/2025 Non-covered Recipient Entity
JITENDRA VASANDANI-MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202513897
Principal investigator 1 Sun Pharmaceutical Industries Inc. $8,277.79 10/02/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
INSPIRE LTE study No dispute reported 06/30/2026 1246432864
Principal investigator 1 Eli Lilly and Company $1,248.22 09/24/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187893898
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $23,859.84 09/19/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285712
Principal investigator 1 ABBVIE INC. $2,350.10 09/03/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202507233
Principal investigator 1 ABBVIE INC. $3,232.20 09/03/2025 Non-covered Recipient Entity
JITENDRA VASANDANI-MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202507235
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,859.20 08/20/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223284399
Principal investigator 1 Sun Pharmaceutical Industries Inc. $10,847.52 08/14/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
INSPIRE LTE study No dispute reported 06/30/2026 1246432940
Principal investigator 1 Sun Pharmaceutical Industries Inc. $5,027.62 08/06/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432873
Principal investigator 1 ABBVIE INC. $2,296.70 08/05/2025 Non-covered Recipient Entity
JITENDRA VASANDANI-MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202501318
Principal investigator 1 ABBVIE INC. $1,250.10 08/05/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202501320
Principal investigator 1 Janssen Research & Development, LLC $1,289.00 08/01/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175307904
Principal investigator 1 SANOFI US SERVICES INC. $4,540.20 07/28/2025 Non-covered Recipient Entity
Jitendra Vasandani Md Pa Jitendra Vasandani Md Pa Dba West Texas Clinical Research
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226082749
Principal investigator 1 Sun Pharmaceutical Industries Inc. $10,343.29 07/23/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
INSPIRE LTE study No dispute reported 06/30/2026 1246432832
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,747.28 07/23/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223282958
Principal investigator 1 Sun Pharmaceutical Industries Inc. $7,558.06 07/11/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432896
Principal investigator 1 Sun Pharmaceutical Industries Inc. $875.00 07/07/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432883
Principal investigator 1 ABBVIE INC. $2,785.00 07/02/2025 Non-covered Recipient Entity
JITENDRA VASANDANI-MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202494799
Principal investigator 1 ABBVIE INC. $2,199.45 07/02/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202495499
Principal investigator 1 SANOFI US SERVICES INC. $4,126.20 07/02/2025 Non-covered Recipient Entity
Jitendra Vasandani Md Pa Jitendra Vasandani Md Pa Dba West Texas Clinical Research
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226082730
Principal investigator 1 SANOFI US SERVICES INC. $1,531.80 07/02/2025 Non-covered Recipient Entity
Jitendra Vasandani Md Pa Jitendra Vasandani Md Pa Dba West Texas Clinical Research
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226082735
Principal investigator 1 Sun Pharmaceutical Industries Inc. $25,497.99 06/25/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
INSPIRE LTE study No dispute reported 06/30/2026 1246432847
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,800.16 06/25/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223281870
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,060.00 06/20/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223281714
Principal investigator 1 Sun Pharmaceutical Industries Inc. $4,957.00 06/13/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432923
Principal investigator 1 Sun Pharmaceutical Industries Inc. $34,392.60 06/11/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432888
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,029.68 06/11/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223281002
Principal investigator 1 Sun Pharmaceutical Industries Inc. $595.32 06/09/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432891
Principal investigator 1 ABBVIE INC. $5,260.60 06/03/2025 Non-covered Recipient Entity
JITENDRA VASANDANI-MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202489247
Principal investigator 1 Janssen Research & Development, LLC $16,807.00 05/26/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175307892
Principal investigator 1 Sun Pharmaceutical Industries Inc. $823.82 05/23/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432981
Principal investigator 1 Sun Pharmaceutical Industries Inc. $618.80 05/22/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
INSPIRE LTE study No dispute reported 06/30/2026 1246432978
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,013.12 05/21/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223279990
Principal investigator 1 Janssen Research & Development, LLC $500.00 05/16/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175307882
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 05/16/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175307912
Principal investigator 1 Janssen Research & Development, LLC $180.00 05/16/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175307920
Principal investigator 1 Sun Pharmaceutical Industries Inc. $473.45 05/13/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
INSPIRE LTE study No dispute reported 06/30/2026 1246432974
Principal investigator 1 ABBVIE INC. $4,914.20 05/06/2025 Non-covered Recipient Entity
JITENDRA VASANDANI-MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202482219
Principal investigator 1 SANOFI US SERVICES INC. $4,788.60 05/05/2025 Non-covered Recipient Entity
Jitendra Vasandani Md Pa Jitendra Vasandani Md Pa Dba West Texas Clinical Research
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226082655
Principal investigator 1 Sun Pharmaceutical Industries Inc. $1,016.42 05/01/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432970
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,882.24 05/01/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223278746
Principal investigator 1 Janssen Research & Development, LLC $967.00 04/28/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175307897
Principal investigator 1 Sun Pharmaceutical Industries Inc. $4,779.32 04/23/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432932
Principal investigator 1 Sun Pharmaceutical Industries Inc. $8,944.83 04/23/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
INSPIRE LTE study No dispute reported 06/30/2026 1246432936
Principal investigator 1 Sun Pharmaceutical Industries Inc. $52,754.83 04/18/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246432928
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,706.56 04/18/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223278474
Principal investigator 1 SANOFI US SERVICES INC. $9,066.60 04/14/2025 Non-covered Recipient Entity
Jitendra Vasandani Md Pa Jitendra Vasandani Md Pa Dba West Texas Clinical Research
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226082652
Principal investigator 1 UCB SA $194.01 04/07/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246659440
Principal investigator 1 Sun Pharmaceutical Industries Inc. $84,863.98 04/04/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432869
Principal investigator 1 ABBVIE INC. $3,207.70 04/03/2025 Non-covered Recipient Entity
JITENDRA VASANDANI-MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202473667
Principal investigator 1 ABBVIE INC. $4,561.95 04/03/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202474115
Principal investigator 1 Sun Pharmaceutical Industries Inc. $6,150.33 04/02/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
INSPIRE LTE study No dispute reported 06/30/2026 1246432919
Principal investigator 1 Sun Pharmaceutical Industries Inc. $1,685.51 03/24/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432968
Principal investigator 1 SANOFI US SERVICES INC. $14,352.00 03/17/2025 Non-covered Recipient Entity
Jitendra Vasandani Md Pa Jitendra Vasandani Md Pa Dba West Texas Clinical Research
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226082637
Principal investigator 1 Sun Pharmaceutical Industries Inc. $5,031.18 03/17/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432903
Principal investigator 1 Janssen Research & Development, LLC $1,123.00 03/10/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175307875
Principal investigator 1 Sun Pharmaceutical Industries Inc. $27,919.19 03/07/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432838
Principal investigator 1 ABBVIE INC. $8,080.20 03/06/2025 Non-covered Recipient Entity
JITENDRA VASANDANI-MD PA
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202456778
Principal investigator 1 ABBVIE INC. $2,500.20 03/06/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202456781
Principal investigator 1 Sun Pharmaceutical Industries Inc. $23,342.58 03/03/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
INSPIRE LTE study No dispute reported 06/30/2026 1246432859
Principal investigator 1 SANOFI US SERVICES INC. $9,080.40 02/18/2025 Non-covered Recipient Entity
Jitendra Vasandani Md Pa Jitendra Vasandani Md Pa Dba West Texas Clinical Research
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226082601
Principal investigator 1 Sun Pharmaceutical Industries Inc. $1,986.22 02/10/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246432899
Principal investigator 1 Sun Pharmaceutical Industries Inc. $308.16 02/10/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432963
Principal investigator 1 ABBVIE INC. $4,398.90 02/05/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202444710
Principal investigator 1 ABBVIE INC. $3,301.00 02/05/2025 Non-covered Recipient Entity
JITENDRA VASANDANI-MD PA
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202445230
Principal investigator 1 Sun Pharmaceutical Industries Inc. $328.10 02/04/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
INSPIRE LTE study No dispute reported 06/30/2026 1246432958
Principal investigator 1 Sun Pharmaceutical Industries Inc. $37,593.47 02/03/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432915
Principal investigator 1 Janssen Research & Development, LLC $3,138.00 01/31/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175307869
Principal investigator 1 Sun Pharmaceutical Industries Inc. $491.85 01/28/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
INSPIRE LTE study No dispute reported 06/30/2026 1246432954
Recipient Eli Lilly and Company $3,033.46 01/27/2025 Covered Recipient Physician EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187871047
Principal investigator 1 Sun Pharmaceutical Industries Inc. $19,730.38 01/27/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
INSPIRE LTE study No dispute reported 06/30/2026 1246432945
Principal investigator 1 Eli Lilly and Company $177,760.00 01/21/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187893802
Principal investigator 1 Sun Pharmaceutical Industries Inc. $1,757.52 01/21/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432949
Principal investigator 1 SANOFI US SERVICES INC. $11,812.80 01/17/2025 Non-covered Recipient Entity
Jitendra Vasandani Md Pa Jitendra Vasandani Md Pa Dba West Texas Clinical Research
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226082597
Principal investigator 1 Sun Pharmaceutical Industries Inc. $7,929.66 01/10/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246432879
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $27,360.97 01/08/2025 Non-covered Recipient Entity
West Texas Clinical Research
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment No dispute reported 06/30/2026 1235991690
Principal investigator 1 UCB SA $67,689.00 01/06/2025 Non-covered Recipient Entity
JITENDRA VASANDANI MD PA
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246657038
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,000.00 01/03/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223273563
Principal investigator 1 ABBVIE INC. $2,307.45 01/02/2025 Non-covered Recipient Entity
WEST TEXAS CLINICAL RESEARCH
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202434442
Principal investigator 1 ABBVIE INC. $2,288.40 01/02/2025 Non-covered Recipient Entity
JITENDRA VASANDANI-MD PA
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202435083